



## **Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City**

SAN CARLOS, Calif., Sept 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2009 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Tuesday, September 22, 2009 at 10:30 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: <http://www.nektar.com>. This Webcast will be available for replay until October 25, 2009.

### About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at <http://www.nektar.com>.

#### Nektar Contacts:

Jennifer Ruddock  
Nektar Therapeutics  
650-631-4954  
[jruddock@nektar.com](mailto:jruddock@nektar.com)

Susan Noonan  
The SAN Group  
212-966-3650  
[susan@sanoonan.com](mailto:susan@sanoonan.com)

SOURCE Nektar Therapeutics

<http://www.nektar.com>

Copyright (C) 2009 PR Newswire. All rights reserved